Revised guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market

Draft

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adoption of guideline (revision 1) by CVMP</td>
<td>8 December 2016</td>
</tr>
<tr>
<td>Draft revised guideline (revision 2) agreed by Safety Working Party (SWP-V)</td>
<td>19 September 2018</td>
</tr>
<tr>
<td>Adoption by CVMP for release for consultation</td>
<td>6 December 2018</td>
</tr>
<tr>
<td>Start of public consultation</td>
<td>18 December 2018</td>
</tr>
<tr>
<td>End of consultation (deadline for comments)</td>
<td>31 August 2019</td>
</tr>
</tbody>
</table>

This guideline updates the CVMP Guideline on safety and residue data requirements for veterinary medicinal products intended for minor uses or minor species/limited market (EMEA/CVMP/SWP/66781/2005-Rev.1).

Comments should be provided using this template. The completed comments form should be sent to vet-guidelines@ema.europa.eu

**Keywords**

Minor use, minor species, safety data, residue data, veterinary medicinal products

© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.
Revised guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market

Table of contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive summary</td>
<td>4</td>
</tr>
<tr>
<td>1. Introduction</td>
<td>4</td>
</tr>
<tr>
<td>2. Scope</td>
<td>6</td>
</tr>
<tr>
<td>3. Definitions</td>
<td>6</td>
</tr>
<tr>
<td>4. Legal basis</td>
<td>7</td>
</tr>
<tr>
<td>5. MRL Applications for minor species with no MRL established for other species – General requirements</td>
<td>7</td>
</tr>
<tr>
<td>5.1. Safety data requirements</td>
<td>7</td>
</tr>
<tr>
<td>5.1.1. Establishment of the ADI and MRL in a minor species</td>
<td>8</td>
</tr>
<tr>
<td>5.1.2. Pharmacological data</td>
<td>8</td>
</tr>
<tr>
<td>5.1.3. Toxicological data</td>
<td>8</td>
</tr>
<tr>
<td>5.2. Residue data requirements</td>
<td>8</td>
</tr>
<tr>
<td>5.2.1. Total residue studies</td>
<td>8</td>
</tr>
<tr>
<td>5.2.2. Marker Residue Studies</td>
<td>9</td>
</tr>
<tr>
<td>5.2.3. Regulatory Analytical Methods</td>
<td>9</td>
</tr>
<tr>
<td>5.3. Establishment of MRLs for honey</td>
<td>9</td>
</tr>
<tr>
<td>6. MRL Applications for minor species where MRLs have been established for other species – General requirements</td>
<td>10</td>
</tr>
<tr>
<td>6.1. Safety data requirements</td>
<td>10</td>
</tr>
<tr>
<td>6.1.1. Establishment of the ADI and MRL in a minor species</td>
<td>10</td>
</tr>
<tr>
<td>6.2. Residue data requirements</td>
<td>10</td>
</tr>
<tr>
<td>6.2.1. Extrapolation of MRLs from major to minor species</td>
<td>10</td>
</tr>
<tr>
<td>7. Marketing authorisation applications for food producing minor species – General requirements</td>
<td>11</td>
</tr>
<tr>
<td>7.1. Safety data requirements</td>
<td>11</td>
</tr>
<tr>
<td>7.1.1. Tabulated minimum datasets</td>
<td>11</td>
</tr>
<tr>
<td>7.1.2. Marketing Authorisation applications and the use of MRL summary report or EPMARs in accordance with Directive 2001/82/EC, as amended</td>
<td>11</td>
</tr>
<tr>
<td>7.1.3. Pharmacological data</td>
<td>11</td>
</tr>
<tr>
<td>7.1.4. Toxicological data</td>
<td>12</td>
</tr>
<tr>
<td>7.1.5. User safety assessment</td>
<td>12</td>
</tr>
<tr>
<td>7.1.6. Environmental safety</td>
<td>12</td>
</tr>
<tr>
<td>7.2. Residue data requirements</td>
<td>13</td>
</tr>
<tr>
<td>7.2.1. Withdrawal periods for minor species</td>
<td>13</td>
</tr>
</tbody>
</table>
8. Marketing authorisation applications for non-food producing minor species – General requirements
8.1. Safety data requirements
8.1.1. Tabulated minimum datasets
8.1.2. Marketing Authorisation applications and the use of MRL SR or EPMARs in accordance with Directive 2001/82/EC, as amended
8.1.3. Pharmacological data
8.1.4. Toxicological data
8.1.5. User safety assessment
8.1.6. Environmental safety
9. Summary tables of data requirements
References
Executive summary

In order to stimulate the research, development and innovation of new veterinary medicines intended for minor uses or minor species (MUMS)/limited market the CVMP developed guidelines on data requirements for MUMS/limited market veterinary medicinal products for quality, safety and efficacy for pharmaceuticals and a guideline for immunologicals. These guidelines are intended to reduce data requirements where possible for products classified as MUMS/limited market while still providing assurance of appropriate quality, safety and efficacy and complying with the legislation in place and leading to an overall positive benefit-risk balance for the product.

These MUMS guidelines have now been reviewed and revised with the aim of updating the acceptable data requirements in light of experience gained and clarifying, where appropriate, the applicability of the MUMS data requirements. This guideline describes the data requirements regarding safety and residues for pharmaceutical veterinary medicinal products, and MRL application falling within the scope of MUMS/limited market. With regards to the safety data requirements the key consideration is whether the veterinary medicine is intended for treatment of a minor species rather than whether is designated as ‘minor use’ or ‘limited market’.

This guideline also presents several opportunities to waive animal testing requirements for veterinary medicines intended for MUMS/limited market, which is in line with the recent implementation of Directive 2010/63/EC (regarding the protection of animals used for experimental and other scientific purposes) and the 3Rs principles of replacement, reduction and refinement.

This update introduces the extrapolation criteria to be considered by the CVMP when assessing applications for MRLs, and refers to Commission Regulation (EU) 2017/880 of 23 May 2017 laying down rules on the use of a maximum residue limit established for a pharmacologically active substance in a particular foodstuff derived from the same species and a maximum residue limit established for a pharmacologically active substance in one or more species for other species, in accordance with Regulation (EC) No 470/2009 of the European Parliament and of the Council (5).

These updated criteria should enable applicants to provide the minimum required data to increase the availability of medicines for both major and minor species, by allowing the CVMP to set MRLs for additional animal species and commodities.

1. Introduction

For some time there has been considerable concern amongst all parties concerned with animal health in the EU about the lack of authorised veterinary medicinal products for minor uses and for minor species. The availability of safe and effective veterinary medicinal products for minor uses or minor species (MUMS)/limited market will improve both animal welfare, animal health and, in some cases, public health. The Agency at the behest of its Management Board began discussions and consultations on this increasing problem in 1998 and, since that time, the CVMP has worked on the matter and is active in initiatives to address the problem of lack of veterinary medicines.

One of the initial measures introduced by the CVMP was to review data requirements for veterinary medicinal products intended for MUMS, both for pharmaceuticals and immunologicals, and, if possible, to establish standards for demonstration of quality, safety and efficacy for these. A set of CVMP guidelines on data requirements for veterinary medicinal products intended for minor use minor species were finalised in 2006 to 2008 (EMEA/CVMP/QWP/128710/2004, EMEA/CVMP/SWP/66781/2005, EMEA/CVMP/EWP/117899/2004, EMA/CVMP/TWP/123243/2006).
Since then the Agency Policy for classification and incentives for veterinary medicinal products indicated for MUMS/limited markets was established and implemented on 1 September 2009 and updated in December 2014 (EMA/308411/2014). The policy is supported by a guidance document on the classification of veterinary medicinal products indicated for minor use minor species (MUMS) / limited market (EMA/CVMP/388694/2014) providing guidance for implementing the policy and the procedure and criteria for classification of products or applications as MUMS/limited market.

The policy is intended to stimulate the development of new veterinary medicines for minor species and for diseases occurring infrequently or in limited geographical areas in major species that would otherwise not be developed in the current market conditions. The guidelines on data requirements for products classified as MUMS/limited market are an integral part of the policy.

These guidelines are intended to reduce data requirements where possible for products classified as MUMS/limited market while still providing assurance of appropriate quality safety and efficacy and complying with the legislation in place and leading to an overall positive benefit-risk balance for the product.

In addition, the reduced data requirements for MUMS has the potential to reduce the numbers of animals used in testing, which is in line with the principles of the 3Rs (reduce, refine, replace), in line with Directive 2010/63.

These guidelines have now been reviewed and revised with the aim of updating the acceptable data requirements in light of experience gained and clarifying, where appropriate, the applicability of the MUMS data requirements.

It is the intention to provide clear guidance under which circumstances data requirements can be reduced for MUMS/limited market products to facilitate the applicant’s work for estimating the required resources for a MUMS/limited market application and preparing the application dossier and provide for predictability. However, it is recognised that this is not always feasible as not all possible scenarios can be addressed in a general guidance document.

Furthermore, the specific requirements will depend on the data and knowledge available, e.g. there may be scope for data reductions if a product has already been authorised for a major species, an MRL has been established for another species, or if a product contains an active substance belonging to a well-known class of substances. However, for products containing entirely new active substances, novel therapy products or products representing first in class, the possibilities for data reduction are likely to be limited. Similarly, for products presenting a specific risk, e.g. for products containing an antimicrobial or vaccines containing genetically modified organisms (GMOs), the possibility for reducing data requirements will be severely limited in the area related to addressing the risk, i.e. adequate data to justify the indication and establish the appropriate dosage regimen or data to ensure safe and efficacious use of such a vaccine will need to be established, even if the product is classified as MUMS/limited market.

The general aim of this guideline is to define acceptable data requirements for safety and residues documentation for veterinary medicinal products intended for minor uses or minor species. In this context, data requirements for the demonstration of safety will be influenced to a certain extent by the active substance/product type and whether or not the product is/has been authorised in a related major species for the same or a similar route of administration. It follows that where an active substance/product is or has been authorised for the same or a similar route of administration in a major species, information relating to use in that species may be used in support of the application and, where justified, this may obviate the need for certain toxicity studies. For novel active substances and for those where limited information is available relating to their use in any animal species, comprehensive toxicity information will be required. In accordance with the provisions of the European
Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes and Directive 2010/63/EU on protection of animals used for scientific purposes, the 3R principles (replacement, reduction and refinement) should be applied to in regulatory testing of pharmaceuticals.

The guidance provided in this document is general. Applicants are advised to request scientific advice on their individual data package to confirm the precise requirements for their specific application.

2. Scope

The objective of this guideline is to clarify the requirements as follows:

- The data requirements for minor species for a Maximum Residues Limit (MRL) application with no MRL established for other species.
- The data requirements for minor species for an MRL application where an MRL has been established for other species.
- The data requirements for a marketing authorisation application for a minor food producing species.
- The data requirements for a marketing authorisation application for a minor non-food producing species.

As a general principle, the CVMP and VICH guidelines concerning safety and residues are applicable to minor use/minor species products.

3. Definitions

Definitions are provided in the revised policy for classification and incentives for veterinary medicinal products indicated for minor use minor species (MUMS)/limited market (EMA/308411/2014).

Minor species: There is no legislative definition in the EU for major or minor species.

Major species have been defined by the CVMP as follows:

- Major food-producing species:
  - cattle (dairy and meat animals);
  - sheep (meat animals);
  - pigs;
  - chickens (including laying hens);
  - salmon.

- Major companion animal species:
  - cats;
  - dogs.

All other animal species, which are not considered major, are as a consequence, by default, classed as minor species.

---

1 Salmon should be considered a major species, however other species of the Salmonidae family such as rainbow trout should be considered minor species. The term salmon is understood in this context as Atlantic salmon (Salmo salar).
Minor use: Minor use in a major species is generally considered as the use of veterinary medicinal products for the treatment of diseases that occur infrequently or occur in limited geographical areas and thus are indicated for a smaller market sector.

Limited market: A market for a veterinary medicinal product that is limited in size due to the product being indicated for a disease or condition that represents a minor use in a major species or that occurs in a minor species.

4. Legal basis


Requirements for safety testing for a marketing authorisation application are laid down in Article 12 of Directive 2001/82/EC, and are specified in Annex I of Directive 2001/82/EC, Title I for pharmaceuticals, as amended by Directive 2009/9/EC.

One of the intentions of the legislation in place for the authorisation of veterinary medicines as laid down in the preamble of Directive 2001/82/EC, preamble point Nos. 9 and 10 of Directive 2004/28/EC, is to facilitate the authorisation of certain veterinary medicinal products:

'(9) The costs of research and development to meet increased requirements as regards the quality, safety and efficacy of veterinary medicinal products are leading to a gradual reduction in the range of products authorised for the species and indications representing smaller market sectors.'

'(10) The provisions of Directive 2001/82/EC also need, therefore, to be adapted to the specific features of the sector, particularly to meet the health and welfare needs of food-producing animals on terms that guarantee a high level of consumer protection, and in a context that provides adequate economic interest for the veterinary medicinal products industry.'

This is also reflected in Annex I of Directive 2001/82/EC under Introduction and General Principles. (10) In cases of applications for marketing authorisations for veterinary medicinal products indicated for animal species and indications representing smaller market sectors, a more flexible approach may be applicable. In such cases, relevant scientific guidelines and/or scientific advice should be taken into account.

5. MRL Applications for minor species with no MRL established for other species – General requirements

5.1. Safety data requirements

Food derived from a minor species usually constitutes a small proportion of the diet of the average European consumer. It may, nevertheless, constitute a major portion of the intake of animal derived products in certain geographic areas or for certain subpopulations and therefore consumer safety must not be compromised.
It was concluded that the standard safety data requirements relating to any effects that might occur after single and repeated exposure could not be reduced for minor species.

5.1.1. Establishment of the ADI and MRL in a minor species

Table 1. presents the data requirements for testing the safety (i.e. pharmacology and toxicology) of those substances that are used in minor food-producing species and for the establishment of an MRL, where MRLs have not been established for use in a major food-producing species. It should be noted that for the safety evaluation, the data requirements are broadly the same as for major species.

5.1.2. Pharmacological data

Pharmacological data must provide sufficient information for an assessment of the pharmacodynamic effects (i.e. primary and secondary pharmacodynamics) in order to establish whether a pharmacological ‘acceptable daily intake’ (ADI) is required. Pharmacological studies may assist in the understanding of toxicological phenomena or show pharmacological effects in the absence of toxicological responses. Thus, if there are no human data, details of pharmacodynamic studies in laboratory animals are required. However, an abbreviated dataset not including pharmacodynamic studies may be considered, depending on the substance under consideration, but the absence of data must be scientifically justified with a summary of anticipated pharmacodynamic effects.

Pharmacokinetic studies in laboratory animals, and if available, human data should be submitted for the assessment of the fate of the substance. These are fundamental data that are required for selection of appropriate species for toxicity studies and the establishment of an ADI and MRLs.

5.1.3. Toxicological data

Toxicological data are required for an assessment of adverse effects and to establish a toxicological ADI and the dataset must be sufficient to establish this. CVMP/VICH guidelines should be followed with regard to the choice of the studies required by this guideline and the toxicological tests themselves should be conducted in accordance with the relevant OECD or other internationally recognised guidelines. Any deviation should be adequately justified.

5.2. Residue data requirements

5.2.1. Total residue studies

Total residue (radiolabelled) studies will normally be required for most veterinary substances to identify the residue of concern in the minor species and to establish the ratio of the marker residue(s) to total residues, if necessary. Possible exemptions are substances where there is evidence that the only residues of concern are known and can be determined by validated analytical methods (e.g. pharmacologically or microbiologically active component in case of pharmacological/microbiological ADI). For a novel compound intended for minor species, the requirement for a radiolabelled study could be waived on a case-by-case basis upon request when scientifically justified and supported by substitute data. The applicant could request the CVMP to give scientific advice on this issue before the application is submitted to EMA. The advice of the CVMP may be based on the following considerations:

i. available absorption, distribution, metabolism and excretion (ADME) data (e.g. in laboratory species) that may be extrapolated to the minor species.
ii. if the novel compound belongs to a class of (veterinary or human) medicines of which it has
been shown, in ADME studies in laboratory animals or other target species, that one or more of
the following apply:

- such medicines are not or are hardly metabolised,
- the metabolism of such medicines is well known and comparable (within the chemical class
and across species),
- structural differences between the novel compound and other substances of the same class
of drugs are not indicative for a significantly different metabolism,

and:

- there is no indication of metabolites or degradation products of specific concern,
- the parent compound of such medicines can be considered as a suitable marker residue for
surveillance,
- the information on the metabolism of such medicines provides an estimate of the ratio of
marker to total residues, which can be used, for the calculation of the intake of residues
resulting from the proposed MRLs.

There are two other exemptions from the rule. As detailed in the Note for guidance on the
establishment of MRL for Salmonidae and other fin fish (EMEA/CVMP/153b/97 FINAL), in fish the
parent compound is normally acceptable as a valid marker residue and radiolabelled studies are not
required. Radiolabelled studies are also not required to establish an MRL for a substance in honey.

5.2.2. Marker Residue Studies

Where MRLs need to be established in the minor species, marker residue depletion studies in
accordance with the requirements of Commission Regulation (EU) 2018/782 should be submitted.

5.2.3. Regulatory Analytical Methods

For the purposes of monitoring residues, there is also a need for a regulatory analytical method for
minor species. However, a reduced validation of the proposed regulatory analytical method could be
acceptable. The method should be validated in respect of the limit of quantification (LOQ) and, at least,
for accuracy and precision at the level of the MRL and half the MRL. With regard to specificity, possible
interference from matrix components and from chemically closely-related substances used in
veterinary therapy should be investigated. Adequate storage and sample processing stability data
should also be supplied.

5.3. Establishment of MRLs for honey

The establishment of MRLs in honey requires residue studies. While the determination of a theoretical
safe level in honey could, in principle, be calculated directly from the ADI or the portion of the ADI
available, an MRL cannot be set without knowing the residue concentrations that would typically occur
in practice. Current requirements for residue studies in honey are given in Commission Regulation (EU)
2018/782 and in VICH GL56.

Assessment of residues in honey is more complex than in mammalian or avian tissues. In honey, there
is no time dependent depletion/elimination of residues as a result of pharmacokinetics (as in
mammalian/avian tissues). Residues, once present in honey, largely remain there. Apart from possible
chemical degradation of a substance in honey matrix over time, the main variable responsible for the
level of residues at harvest time is the honey yield (dilution effect), which in large part depends on the
production site (geographical area) and weather conditions at flowering time. These variables are
unpredictable and not directly related to a specifiable period of time. Therefore, the only feasible
withdrawal period in honey is a 'zero' withdrawal period. Residue studies covering a reasonable range
of commercial treatment conditions are needed to support this 'zero' withdrawal period. These studies
should show that there are no non-conforming residues (i.e. above the MRL) under conditions of good
bee keeping practice.

6. MRL Applications for minor species where MRLs have been
established for other species – General requirements

6.1. Safety data requirements

For substances where MRLs have already been established for other species, the safety data must have
been submitted and evaluated in order for a reduced data set to be considered when establishing MRLs
in minor species. The outcome of the previous evaluation could have resulted in the establishment of
an ADI and subsequently MRLs. It is also possible that no ADI was established, resulting in a 'no MRL
required' entry in Regulation 37/2010. These substances are normally considered as safe, but the 'no
MRL required' entry could be restricted to a particular route of administration, or have been intended
only for minor species, and previous 'rules' had been applied, resulting in a reduced data requirement
for the safety package. In such instances, safety data may be required, depending on the application
submitted.

6.1.1. Establishment of the ADI and MRL in a minor species

For substances where the ADI has already been established, no additional safety data are required.
The ADI that has already been determined can be used to establish MRLs in the minor species,
 together with the relevant residue data.

In situations where no ADI has been determined for a substance but with a 'no MRL required' entry for
other species, possibly with a restriction (e.g., For topical use only), if the MRL that has been sought is
without any restriction, then safety data as set out in section 5 above will be required.

6.2. Residue data requirements

Once the need for the establishment of MRLs for the minor species has been identified, the first point
to consider is whether extrapolation of MRLs established in other species to the minor species is
possible. The criteria for extrapolation are set out in 6.2.1 below. If extrapolation is not possible, then
residue data as set out in section 5.2 above are required.

6.2.1. Extrapolation of MRLs from major to minor species

Previously, much effort by the CVMP regarding availability of veterinary medicines focussed on
extrapolation of existing MRLs from major species to minor species and significant progress has been
made in this area; guidance has been developed (CVMP Note for Guidance on the Establishment of
Maximum Residue Limits for Minor Animal Species, EMEA/CVMP/153a/97 and Note for Guidance on the
Risk Analysis Approach for Residues of Veterinary Medicinal Products in Food of Animal Origin,
EMEA/CVMP/187/00-FINAL). The principle of extrapolation received legal backing when it was
incorporated in Article 5 of Regulation (EC) 470/2009. The CVMP now actively considers whether
extrapolation would be possible to other species and food commodities as part of its MRL evaluations, in line with Commission Regulation 2017/880, laying down rules on the use of a maximum residue limit established for a pharmacologically active substance in a particular foodstuff for another foodstuff derived from the same species and a maximum residue limit established for a pharmacologically active substance in one or more species for other species, in accordance with Regulation (EC) No 470/2009 of the European Parliament and of the Council.

Regulation 2017/880 sets out the considerations that the CVMP will undertake for all new MRL applications in terms of potential extrapolation opportunities. Included in this are the minimum criteria for extrapolation, which may not be met in all cases, but could be met with minimal additional data where these are available. It should be noted that the potential extrapolation opportunities have been considerably increased by adoption of this regulation. Applicants are invited to actively consider these opportunities when applying for MRLs.

7. Marketing authorisation applications for food producing minor species – General requirements

7.1. Safety data requirements

The requirements for Marketing Authorisations for food producing species as given in the Directive 2001/82/EC as amended and the CVMP/VICH Safety guidelines were considered and reductions in the safety data requirements have been identified.

7.1.1. Tabulated minimum datasets

Table 2 presents the data requirements for safety testing (i.e., pharmacology and toxicology) for a Marketing Authorisation for minor food producing species where there are MRLs established for the active ingredients, in accordance with Part 3A Safety Testing as laid down in Annex I of Directive 2001/82/EC, as amended by Directive 2009/9/EC. As substances with MRLs are likely to have a published Summary Report (SR) or European Public MRL Assessment Report (EPMAR), information from these publications may be used in support of the pharmacology and toxicology part of the application dossier.

7.1.2. Marketing Authorisation applications and the use of MRL summary report or EPMARs in accordance with Directive 2001/82/EC, as amended

It should be noted that Directive 2001/82/EC, as amended, permits Marketing Authorisation applications made in accordance with Article 13a, to submit the published EMA/CVMP SR/EPMAR as published literature, particularly for the safety tests, thus allowing an exemption for pharmacological and toxicological data. Article 13a refers to applications made on the basis of ‘well-established use’ and permits the submission of ‘appropriate scientific literature’ in place of study data. Therefore, when an MRL has been established for a substance for a major or minor food producing species, it will be possible for the Marketing Authorisation applicant to submit the EMA/CVMP MRL SR/EPMAR as part of the published literature submitted. These data can also be used for MAAs intended for non-food species (see section 8.1.2), if available.

7.1.3. Pharmacological data

Pharmacological studies in laboratory animals (Part 3.A of the dossier) and the target species (Part 3.B) can be replaced by cross reference to the target species studies submitted in Part 4 of the

Revised guideline on safety and residue data requirements for pharmaceutical veterinary medicinal products intended for minor use or minor species (MUMS)/limited market
EMA/CVMP/SWP/66781/2005–Rev.2
dossier, by means of a summary of any observed effects in the pharmacodynamics studies and a
summary of the pharmacokinetics data to include absorption, distribution, metabolism and excretion
(ADME). The pharmacokinetics of the active substance following oral exposure to residues will have
been considered as part of the MRL application and cross reference can be made to the EMA/CVMP MRL
SR/EPMAR.

7.1.4. Toxicological data

Where there is no MRL SR or EPMAR available, toxicological data are required for the evaluation of user
safety and the assessment of adverse effects. For example, the data set must be adequate for the
evaluation of possible adverse effects on fertility or reproduction. It should also consider potential
problems associated with administration, such as exposure by inhalation or dermal contact and
accidental self-injection. The omission of studies should be adequately justified.

Where available, CVMP/VICH guidelines should be followed and the toxicological tests themselves
should be conducted in accordance with the relevant OECD guidelines or other internationally
recognised guidelines and any deviation should be justified. The toxicology of the active substance
following oral exposure to residues will have been considered as part of the MRL application and cross
reference can also be made to the EMA/CVMP MRL SR/EPMAR. See the user safety section below for
further guidance.

7.1.5. User safety assessment

A user risk assessment, considering the administration of the product, and risk management proposals
must be submitted for all applications. The requirements of the user safety guideline
(EMEA/CVMP/543/03-Rev.1) should be applied. This guideline allows for consideration of (low)
exposure frequencies. This assessment should include a discussion of the effects found in the
pharmacological and toxicological data and relate this to the type and extent of human exposure to the
product with a view to formulating appropriate user warnings.

7.1.6. Environmental safety

Environmental safety requirements for minor species and minor use are described in the questions 4
and 5, respectively, of the CVMP/VICH Phase I guidance as given in CVMP/VICH/592/98-FINAL. This
guideline came into force in July 2000, and in view of the modification of the legislation since then, the
following is to be considered for minor species:

An environmental risk assessment (ERA) for minor species is not required in the case where an ERA is
available for a major species, provided that: 1) the minor species is reared under similar conditions as
the major species, and the primary environmental release of the VMP used for minor and major species
is to the same environmental compartment, e.g., soil or water; 2) the exposure to the same
environmental compartment from the use of the minor species is not higher than from the use in the
major species, and the total dose administered to the minor species is no greater that used in the
major species; 3) any risks identified in the major species are also considered in the ERA for the minor
species; and, 4) the ERA of the major species belongs to the same applicant. In that case the ERA
conclusions from the major species also apply to the minor species.

---

2 If a VMP for a major species, for example, is approved for stabled husbandry, with manure as the primary environmental
entry point, the applicant for the same VMP used for a minor species in aquaculture would need to undertake an ERA.
7.2. Residue data requirements

7.2.1. Withdrawal periods for minor species

Whereas the MRL refers to the active chemical substance itself, the withdrawal period refers to, and is dependent on, the specific marketing formulation and dosing regimen (highest dose and longest duration indicated for a particular species) of a veterinary medicinal product (VMP). Each product has to be considered on its own merits. Current guidelines on setting withdrawal periods do not differentiate between minor and major species. Data requirements are practically the same (see Table 4 except in some of the following cases.

Current requirements for residue studies in honey are given in VICH GL56. Draft guidance on residue studies in aquatic species (VICH GL57) is also available.

7.2.1.1. Identical products

In case of the same VMP where the active substance has the same MRL in the major/minor species, following an approach similar to the approach for extrapolation of MRLs could be considered, i.e. no residue depletion studies may be required in the minor species. In accordance with the approach accepted for extrapolation of MRLs, an extrapolation of withdrawal periods should be possible from cattle/sheep to other ruminants, from chickens to other avian species, from Salmonidae to other fin fish, etc. Exemptions are products having a potential to leave local residues (in particular injectable products administered intramuscularly and/or subcutaneously as well as dermal/intramammary applications). In this case, information on the behaviour of residues at the site of administration needs to be assessed before the withdrawal period is extrapolated; limited residue depletion studies (e.g., at 2 time points, one just before the reference withdrawal period and one after it) or alternatively, an uncertainty (safety) factor, to compensate for uncertainties in the extrapolation, could be considered (multiplication of the withdrawal period in the major species by an uncertainty factor of 1.5). Use of an uncertainty factor would only be appropriate if the dose and volume of injection are no greater than that administered in the major species.

7.2.1.2. Products with identical active ingredient but with different formulation/different dosing regimen/routes of administration

Differences in the pharmaceutical composition can have a considerable impact on pharmacokinetic properties and route-to-route or dose-to-dose extrapolations of withdrawal periods might not be feasible, particularly if injectable formulations are involved. With respect to non-identical products, a more cautious approach is necessary and products need to be assessed on a case-by-case basis.

In the case of a multiple administrations of a product, it would be important to know the accumulation profile of the active substance or the marker residue in the minor species. Normally, some experimental information in the minor species will be required to support the withdrawal period. An approach based on limited residue data could be acceptable: pharmacokinetic studies demonstrating similar profiles could provide useful data to support an extrapolation of withdrawal periods between major/minor species. Setting of a withdrawal period in the minor species based on overall pharmacokinetic parameters (e.g., plasma terminal elimination half-life) could be an option for certain compounds (e.g., compounds distributed mainly in extracellular fluids/plasma only).

In the absence of residue data, use of an uncertainty (safety) factor to compensate for uncertainties in the extrapolation could be considered (multiplication of the withdrawal period in the major species by a certain factor, e.g., 1.5) if it is clear that the new formulation is qualitatively and quantitatively similar
to the original formulation and is used at or below the dose used for the original formulation with the same route of administration.

When the product for the minor species is to be used at a significantly higher dose level/dosing regimen, conventional residue studies will be required to confirm the withdrawal period. Where the product for the minor species is intended for injection (intramuscular or subcutaneous), residue data from the injection site will also be needed. Likewise, for veterinary medicinal products for topical applications, local residues in edible tissues below the site of administration need to be investigated.

For residue studies in the minor species the analytical method used in a residue depletion study must be validated in line with VICH GL49 (EMA/CVMP/VICH/463202/2009) otherwise the study itself would not be valid (see below at 7.2.1.4 and also Table 5).

7.2.1.3. Products not authorised previously for major species

Residue studies according to guidelines are normally required for veterinary medicinal products for a minor species where previously no similar product was authorised for a major species.

Extrapolation may be possible if a residue study is available for a minor species in the same category conducted and evaluated according to the guidelines (e.g., turkeys to ducks) (Pharmacokinetic parameters should be comparable, pharmaceutical form, route of administration and dosing regimen should also be the same).

7.2.1.4. Analytical methods (in residue studies supporting withdrawal periods in minor species)

The analytical method used in a residue depletion study must be validated in line with VICH GL49 (EMA/CVMP/VICH/463202/2009) otherwise the study itself would not be valid. See Table 5.

7.2.1.5. Withdrawal periods for compounds with a 'no MRL required' entry

Many compounds with a 'no MRL required' entry have been placed there based on consideration of quick metabolism/elimination of residues and/or limited use (see Annex II criteria in the CVMP Note for Guidance on the Risk Analysis Approach for Residues of Veterinary Medicinal Products in Food of Animal Origin [EMEA/CVMP/187/00-FINAL] Appendix 1). For such compounds, no MRL is available on which to base the withdrawal period. For many compounds with a 'no MRL required' entry there is an established ADI, but there are several compounds for which there is none (e.g., xylazine, levomethadone). For compounds with an ADI, the ADI can serve as a reference point for the withdrawal period. A complication inherent in the ADI approach is that the ADI often relates to total drug derived residues or a combination parent compounds plus metabolites. Consequently, in a strict sense, a withdrawal period based on the ADI would necessitate residue studies for more than a single component, i.e. normally total residue (radiolabelled) studies, which are extremely complex and costly. A request for total residue (radiolabelled) studies for setting withdrawal periods is normally not reasonable or warranted for compounds fulfilling a 'no MRL required' criteria. In this case, it would be sufficient to estimate a withdrawal period based on depletion data for the most relevant residue component in the tissue with the slowest depletion rate (could be the parent compound and/or major metabolite). Supporting information allowing the estimation of food basket residues should be available from the MRL procedure (residue distribution data between tissues, ratios between residue components in tissues). The same consideration applies to compounds with no ADI where an alternative exposure limit (e.g., Tolerable Dietary Intake) may serve as reference point for the withdrawal period.
Withdrawal periods for compounds with a 'no MRL required' entry for which an ADI has been set, it
would be reasonable to use an uncertainty factor (e.g., 1.5) for extrapolating the withdrawal period for
minor species from major species.

8. Marketing authorisation applications for non-food producing minor species – General requirements

8.1. Safety data requirements

The requirements for Marketing Authorisations for non-food-producing species, as given in Annex I to
non-food producing species; therefore, very limited reductions in data requirements were identified
when considering minor species. The specific safety data requirements are listed in Table 3.

8.1.1. Tabulated minimum datasets

Table 3. presents the data requirements for safety testing (i.e., pharmacology and toxicology) for a
Marketing Authorisation for non-food-producing species, in accordance with Part 3A Safety Testing as
laid down in Annex I Directive 2001/82/EC as amended by Directive 2004/28/EC, with the exception of
environmental safety requirements, and in accordance with the CVMP/VICH Safety guidelines.

8.1.2. Marketing Authorisation applications and the use of MRL SR or EPMARs in accordance with Directive 2001/82/EC, as amended

It should be noted that the amending Directive 2004/28/EC permits Marketing Authorisation
applications made in accordance with Article 13a, to submit the published EMEA/CVMP MRL SR/EPMAR
as published literature, particularly for the safety tests, thus allowing an exemption for
pharmacological and toxicological data. Article 13a refers to applications made on the basis of
‘well-established use’ and permits the submission of scientific literature in place of study data.
Therefore, when an MRL has been established for a substance for a major or minor food producing
species, it will be possible for the Marketing Authorisation applicant to submit the EMEA/CVMP MRL SR
or EPMAR as part of the published literature submitted. Therefore MRL SR/EPMAR can be submitted as
part of a bibliographic application in accordance with the amending Directive 2004/28/EC even though
the Marketing Authorisation may be for non-food producing species.

8.1.3. Pharmacological data

Pharmacological studies in laboratory animals can be replaced by cross reference to the target species
studies submitted in Part 4 of the dossier, by means of a summary of any observed effects in the
pharmacodynamic studies and a summary of the pharmacokinetics profile to include absorption,
distribution, metabolism and excretion (ADME). Absence of studies in laboratory animals must be
scientifically justified.

8.1.4. Toxicological data

Toxicological data are required for the assessment of user safety and of adverse effects in the target
animals (e.g., possible adverse effects to fertility or reproduction). It should consider potential
problems associated with administration, such as exposure by inhalation, dermal contact and
accidental self-injection, as necessary. The omission of studies should be adequately justified.
Where appropriate, CVMP/VICH guidelines should be followed and the toxicological tests themselves should be conducted in accordance with the relevant OECD guidelines or other internationally recognised guidelines; any deviation should be justified.

8.1.5. User safety assessment

A user risk assessment of the potential hazards and exposure scenarios from administration of the product to animals, and risk management proposals must be submitted for all applications. The requirements of the user safety guideline (EMEA/CVMP/543/03-Rev.1) should be applied. This guideline allows for consideration of (low) exposure frequencies. This assessment should include a discussion of the effects found in the pharmacological and toxicological data (i.e., hazard identification) and relate this to the type and extent of human exposure to the product, with a view to formulating appropriate user warnings. For topically-applied products, Guideline EMA/CVMP/SWP/721059/2014 should also be applied.

8.1.6. Environmental safety

Environmental safety requirements should be addressed by referring to the CVMP/VICH Phase I guidance as given in CVMP/VICH/592/98-FINAL.

9. Summary tables of data requirements

Table 1. Data requirements for safety testing for establishment of MRLs for minor food-producing species (where no toxicological evaluation has taken place)

Table 2. Data requirements for safety testing for a marketing authorisation for minor food-producing species (where the ADI has already been established or was not considered necessary)

Table 3. Data Requirements for safety testing for a Marketing Authorisation for non-food-producing species

Table 4. Current data requirements for residues studies for MRLs and withdrawal periods

Table 5. Current data requirements for analytical methods
**Table 1.** Data requirements for safety testing for establishment of MRLs for minor food-producing species (where no toxicological evaluation has taken place)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A Safety file</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A2. Pharmacology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 Pharmacodynamics</td>
<td>Details of pharmacodynamic studies in laboratory animals in the absence of human data</td>
<td>Details of pharmacodynamic studies in laboratory animals in the absence of human data may be necessary on a case by case basis, depending on the substance under consideration. A minimum dataset not including pharmacodynamic studies must be justified.</td>
</tr>
<tr>
<td>2.2 Pharmacokinetics</td>
<td>Details of pharmacokinetic studies in laboratory animals, and if available, human data. See VICH GL47.</td>
<td>Same criteria apply.</td>
</tr>
<tr>
<td>A3. Toxicological studies</td>
<td>See VICH GL33</td>
<td></td>
</tr>
<tr>
<td>3.1 Single dose toxicity</td>
<td>Not required. Studies may be submitted where they exist in the study archive or in published literature. Cross refer to any other acute toxicity studies (e.g. user safety studies)</td>
<td>Same criteria apply.</td>
</tr>
<tr>
<td>3.2 Repeat dose toxicity</td>
<td>• 90 day study (See VICH GL31)</td>
<td>Same criteria apply.</td>
</tr>
<tr>
<td></td>
<td>• 2 species, 1 must be non-rodent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Oral administration</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Chronic toxicity study3 (See VICH GL37)</td>
<td></td>
</tr>
<tr>
<td>3.3 Tolerance in the target species</td>
<td>Not required. Relevant data may be submitted if available.</td>
<td>Same criteria apply.</td>
</tr>
<tr>
<td>3.4 Reproductive toxicity including developmental toxicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.4.1 Study of the effects on reproduction</td>
<td>See VICH GL22. Usually need a study in at least one</td>
<td>Same criteria apply.</td>
</tr>
</tbody>
</table>

---

3 The VICH GL37 (Studies to evaluate the safety of residues of veterinary drugs in human food: repeat-dose (chronic) toxicity testing) (CVMP/VICH/468/03-FINAL) indicates that most veterinary drugs will need to be tested for the adverse consequences of chronic exposure, as there is a potential for consumers to be exposed repeatedly throughout their lifetime. However, the guideline does not preclude the possibility of alternative approaches that may offer an equivalent assurance of safety, including scientifically based reasons as to why chronic toxicity testing may not need to be provided.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>species (rat).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral route of administration.</td>
<td></td>
</tr>
<tr>
<td>3.4.2 Study of developmental toxicity</td>
<td>See VICH GL32</td>
<td>Same criteria apply.</td>
</tr>
<tr>
<td>3.5 Genotoxicity</td>
<td>See VICH GL23 (R)</td>
<td>Same criteria apply.</td>
</tr>
</tbody>
</table>
| 3.6 Carcinogenicity         | Long-term animal carcinogenicity bioassays will usually be required for substances to which human beings will be exposed when any of the following criteria apply:  
  - where structure-activity relationships indicate a close chemical analogy with known carcinogens;  
  - where findings in toxicity studies have identified potentially pre-neoplastic lesions or are indicative of neoplasia;  
  - where mutagenicity testing produced results indicating a possibility of carcinogenic effects;  
  - See VICH GL28. | Same criteria apply. |
| A.4 Studies of Other Effects |                                |                                               |
| 4.1 Immunotoxicity          | If immunological effects in repeat dose studies are observed, additional studies are required  
  Additional studies in accordance with current state of scientific knowledge | Same criteria apply. |
| 4.2 Neurotoxicity           | Signs of neurotoxicity after acute or subchronic administration of new compounds in laboratory or target animals may require more detailed studies.  
  - Required if substance belongs to: organophosphates (OPs), pyrethroids, carbamates, avermectins  
  - Oral route (OECD 424 and 426) | Same criteria apply. |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OPs: delayed neurotoxicity: single dose (OECD 418); repeated dose (OECD 419)</td>
<td></td>
</tr>
<tr>
<td>4.3 Microbiological studies</td>
<td>4.3.1 potential effects on the human gut flora</td>
<td>Same criteria apply.</td>
</tr>
<tr>
<td></td>
<td>• Required if there are residues of antimicrobial compounds</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• See VICH GL36</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Assessment of the effect of antimicrobial substances on dairy starter cultures. See EMEA/CVMP/276/1999</td>
<td></td>
</tr>
<tr>
<td>4.3 Microbiological studies</td>
<td>4.3.2 potential effects on the micro-organisms used for industrial food-processing</td>
<td></td>
</tr>
<tr>
<td>4.4 Observations in Humans</td>
<td>Observed effects in human therapy medicinal products.</td>
<td>Same criteria apply.</td>
</tr>
<tr>
<td></td>
<td>All relevant epidemiological, pharmacological, toxicological, and clinical data to be provided.</td>
<td></td>
</tr>
</tbody>
</table>
Table 2. Data requirements for safety testing for a Marketing Authorisation for minor food-producing species (where the ADI has already been established or was not considered necessary)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>For well-established use applications, the MRL SR/EPMAR may be used, if one exists.</td>
<td>For well-established use applications, the MRL SR/EPMAR may be used, if one exists.</td>
</tr>
</tbody>
</table>

**PART III.A SAFETY DOCUMENTATION**

**III.A.2 Pharmacological studies**

2.1 Pharmacodynamics

2.2 Pharmacokinetics

Cross-reference to studies in Part 4. Details of pharmacological studies in laboratory animals and relevant observations in target species.

Same criteria apply.

**III.A.3 Toxicological studies**

3.1 Single dose toxicity

- Data relevant to the assessment of possible effects of accidental administration to humans
- To reduce animal numbers, alternative validated protocols and internationally recognised protocols will be accepted

Same criteria apply.

3.2 Repeat dose toxicity

- 90 day study
- 2 species, 1 must be non-rodent
- Oral administration
- Chronic toxicity study\(^6\)

Same criteria apply.

3.3 Tolerance in the target species

Cross-reference to studies in Part 4, Chapter I, Section B.

Same criteria apply.

3.4 Reproductive toxicity including teratogenicity

3.4.1 Study of the effects on reproduction

Reproduction toxicity study in at least 1 species, usually rodent. See VICH GL22.

Same criteria apply.

3.4.2 Embryotoxic/foetotoxic effects including teratogenicity

At least 1 study conducted in rats, and a 2nd study in another mammalian species, depending on the results of the 1st study. See VICH GL32.

Same criteria apply.

3.5 Genotoxicity

Testing strategy in accordance with current

Same criteria apply.

---


\(^5\) The toxicological data package must allow full assessment of user safety issues and concerns (see CVMP guideline on user safety for pharmaceutical veterinary medicinal products (EMEA/CVMP/543/03-Rev.1))

\(^6\) The VICH GL37 (repeat-dose chronic toxicity testing) indicates that most veterinary drugs will need to be tested for the adverse consequences of chronic exposure, as there is a potential for consumers to be exposed repeatedly throughout their lifetime. However, the guideline does not preclude the possibility of alternative approaches that may offer an equivalent assurance of safety, including scientifically based reasons as to why chronic toxicity testing may not need to be provided.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>For well-established use applications, the MRL SR/EPMAR may be used, if one exists.</td>
<td>state of scientific knowledge (VICH GL23 (R)).</td>
<td>For well-established use applications, the MRL SR/EPMAR may be used, if one exists.</td>
</tr>
</tbody>
</table>

### 3.6 Carcinogenicity

2-year carcinogenicity study in rats required if:

1. active(s) have close chemical analogy with known carcinogens (referred to as 'Structural Alerts'), or,
2. positive mutagenicity tests, or,
3. suspect signs during toxicity testing.

Studies designed in accordance with current state of scientific knowledge

A 2nd study conducted in mice may also be required, in accordance with guidance (VICH GL28).

<table>
<thead>
<tr>
<th>III.A.4 Studies of Other Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1 Special studies</td>
</tr>
</tbody>
</table>

| 4.2 Observations in humans | Observed effects following human exposure, if available. | Same criteria apply. |

| 4.3 Microbiological studies | Required for antibacterial compounds. Investigate risk to human intestinal flora and risk of resistance development. Investigate if residues can affect processes in industrial foodstuffs processes. | Same criteria apply. |

<table>
<thead>
<tr>
<th>4.4 Studies on metabolites, impurities, other substances and formulation</th>
<th>Appropriate studies to assess the toxicity of metabolites, impurities, other substances and formulation</th>
<th>Same criteria apply.</th>
</tr>
</thead>
<tbody>
<tr>
<td>For well-established use applications, the MRL SR/EPMAR may be used, if one exists.</td>
<td>For well-established use applications, the MRL SR/EPMAR may be used, if one exists.</td>
<td></td>
</tr>
</tbody>
</table>

### III.A.5 User safety

The requirements of the user safety guideline (EMEA/CVMP/543/03-Rev.1) should be applied. For topically-applied products, EMA/CVMP/SWP/721059/2014 should also be applied. **Same criteria apply.**

### III.A.6 Ecotoxicity

Environmental Risk Assessment (ERA) in accordance with the existing VICH/CVMP (Phase I/II) Guidelines required. **Same criteria apply.**
<table>
<thead>
<tr>
<th>PART III.A SAFETY DOCUMENTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>III.A.2 Pharmacological studies</td>
</tr>
<tr>
<td>2.1 Pharmacodynamics</td>
</tr>
<tr>
<td>2.2 Pharmacokinetics</td>
</tr>
<tr>
<td>III.A.3 Toxicological studies</td>
</tr>
<tr>
<td>3.1 Single dose toxicity</td>
</tr>
<tr>
<td>3.2 Repeat dose toxicity</td>
</tr>
<tr>
<td>3.3 Tolerance in the target species</td>
</tr>
<tr>
<td>3.4 Reproductive toxicity including teratogenicity</td>
</tr>
<tr>
<td>3.4.1 Study of the effects on reproduction</td>
</tr>
<tr>
<td>3.4.2 Embryotoxic/foetotoxic effects including teratogenicity</td>
</tr>
<tr>
<td>3.5 Genotoxicity</td>
</tr>
</tbody>
</table>

### Table 3. Data requirements for safety testing for a Marketing Authorisation for non-food-producing species

<table>
<thead>
<tr>
<th>Annex I of Directive 2001/82/EC as amended by 2009/9/EC</th>
<th>Standard data requirements: For well-established use applications, the MRL SR/EPMAR may be used, if one exists.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimum dataset for minor non-food-producing species</td>
<td>For well-established use applications, the MRL SR/EPMAR may be used, if one exists.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PART III.A SAFETY DOCUMENTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>III.A.2 Pharmacological studies</td>
</tr>
<tr>
<td>2.1 Pharmacodynamics</td>
</tr>
<tr>
<td>2.2 Pharmacokinetics</td>
</tr>
<tr>
<td>III.A.3 Toxicological studies</td>
</tr>
<tr>
<td>3.1 Single dose toxicity</td>
</tr>
<tr>
<td>3.2 Repeat dose toxicity</td>
</tr>
<tr>
<td>3.3 Tolerance in the target species</td>
</tr>
<tr>
<td>3.4 Reproductive toxicity including teratogenicity</td>
</tr>
<tr>
<td>3.4.1 Study of the effects on reproduction</td>
</tr>
<tr>
<td>3.4.2 Embryotoxic/foetotoxic effects including teratogenicity</td>
</tr>
<tr>
<td>3.5 Genotoxicity</td>
</tr>
</tbody>
</table>

- Cross-reference to studies in Part 4. Details of pharmacological studies in laboratory animals and relevant observations in target species
- Data relevant to the assessment of possible effects of accidental administration to humans
- To reduce animal numbers, alternative validated protocols and internationally recognised protocols will be accepted
- Study in 1 species and this may be replaced by an equivalent study in the target species. Tests may be modified (with justification) for new combinations of known substances. See VICH GL31.
- Cross-reference to studies in Part 4, Chapter I, Section B.
- Not required.
- A study of developmental toxicity in at least one species may be required. The species selected may be the target species. However, the standard package (see Table 2.) is required if use of the product would result in significant exposure to users. See VICH GL32.
- Testing strategy in accordance with current
<table>
<thead>
<tr>
<th>Standard data requirements:</th>
<th>Minimum dataset for minor non-food-producing species</th>
</tr>
</thead>
<tbody>
<tr>
<td>For well-established use applications, the MRL SR/EPMAR may be used, if one exists.</td>
<td>For well-established use applications, the MRL SR/EPMAR may be used, if one exists.</td>
</tr>
</tbody>
</table>

### 3.6 Carcinogenicity

Long term carcinogenicity study required if:

- active has a close chemical analogy with known carcinogens (referred to as ‘Structural Alerts’), or,
- positive mutagenicity tests, or,
- suspect signs during toxicity testing.

Studies designed in accordance with current state of scientific knowledge. See VICH GL28.

### III.A.4 Studies of Other Effects

4.1 Special studies

Special studies including specific target organ toxicity (e.g. immunotoxicity, endocrine function tests, liver and renal function tests, effects on enzymes, neurotoxicity, sensitisation, skin and eye irritation, inhalation toxicity, mechanistic studies, relay toxicity studies, etc. as appropriate).

Data not required unless relevant effects in repeat dose studies have been observed.

4.2 Observations in humans

Observed effects in human therapy medicinal products.

Same criteria apply.

4.3 Microbiological studies

Not required.

4.4 Studies on metabolites, impurities, other substances and formulation

Appropriate studies to assess the toxicity of metabolites, impurities, other substances and formulation.

Same criteria apply.

### III.A.5 User safety

The requirements of the user safety guideline (EMEA/CVMP/543/03-Rev.1) should be applied.

For topically-applied products, EMA/CVMP/SWP/721059/2014 should also be applied.

Same criteria apply.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>For well-established use applications, the MRL SR/EPMAR may be used, if one exists.</td>
<td>For well-established use applications, the MRL SR/EPMAR may be used, if one exists.</td>
</tr>
</tbody>
</table>

| III.A.6 Ecotoxicity | Environmental Risk Assessment (ERA) in accordance with the existing VICH/CVMP (Phase I/II) Guidelines required. | Same criteria apply. |
Table 4. Current data requirements for residues studies for MRL and withdrawal periods (see text of document for possibilities for extrapolation)

<table>
<thead>
<tr>
<th>Establishment of MRLs (6)</th>
<th>Establishment of withdrawal periods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major Species</td>
<td>Minor Species</td>
</tr>
<tr>
<td>Major Species</td>
<td>Minor Species</td>
</tr>
<tr>
<td>Meat: Muscle (including injection site), fat (skin+fat for pigs and poultry), liver, kidney, Muscle and skin in natural proportions for fish</td>
<td>A residues depletion study with 1-4 animals and a sampling timepoint where tissue concentrations are predicted to be close to the MRL. Extrapolation is also possible. See criteria in Regulation 2017/880</td>
</tr>
<tr>
<td>Large animals (mammals): 4 animals/time point</td>
<td>Minimum 4 animals/time point at a minimum of 4 time points as stated in VICH GL48 (R)</td>
</tr>
<tr>
<td>Poultry: 6 animals/time point</td>
<td>No specific conditions for minor species. Under certain conditions, withdrawal periods could be extrapolated from major species. See main text.</td>
</tr>
<tr>
<td>Fish: 10 animals/time point</td>
<td>Samples of milk from at least 20 animals, as set out in VICH GL48 (R)</td>
</tr>
<tr>
<td>(for all species usually 4-5 time points recommended)</td>
<td>No specific conditions for minor milk-producing species.</td>
</tr>
<tr>
<td>See VICH GL46</td>
<td>Extrapolation is also possible. See criteria in Regulation 2017/880</td>
</tr>
<tr>
<td>Extrapolation is also possible. See criteria in Regulation 2017/880</td>
<td>Extrapolation is also possible. See criteria in Regulation 2017/880</td>
</tr>
<tr>
<td>Milk</td>
<td>No specific conditions for minor milk-producing species.</td>
</tr>
<tr>
<td>≥8 as in VICH GL4</td>
<td>Samples of milk from at least 20 animals, as set out in VICH GL48 (R)</td>
</tr>
<tr>
<td>Extrapolation is also possible. See criteria in Regulation 2017/880</td>
<td>No specific conditions for minor milk-producing species. Under certain conditions, withdrawal periods could be extrapolated from major species. See main text.</td>
</tr>
<tr>
<td>Egg</td>
<td>No specific conditions for minor eggs-producing species.</td>
</tr>
<tr>
<td>≥10 eggs/day for laying birds over a sufficiently long time period. VICH GL46</td>
<td>At least 10 eggs per time point, as set out in VICH GL48 (R)</td>
</tr>
<tr>
<td>No specific conditions for minor egg-producing species. Extrapolation is also possible. See criteria in Regulation 2017/880</td>
<td>No specific conditions for minor egg-producing species. Under certain conditions, withdrawal periods could be extrapolated from major species. See main text.</td>
</tr>
</tbody>
</table>

---

7 It should be noted the possible extrapolation of MRLs recommended in one species/food commodity to a second species/food commodity is considered by CVMP as part of its evaluation of the application for the establishment of MRLs in the first species. While applicants can provide data to support the extrapolation of proposed MRLs, companies cannot make stand-alone applications for the extrapolation of established MRLs.
<table>
<thead>
<tr>
<th>Establishment of MRLs (6)</th>
<th>Establishment of withdrawal periods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Honey</td>
<td>6 colonies per site, 4 sites. See VICH GL56</td>
</tr>
</tbody>
</table>

major species. See main text.
**Table 5.** Current data requirements for analytical methods

<table>
<thead>
<tr>
<th>Routine Analytical Method proposed for residues monitoring</th>
<th>Analytical Method validation for withdrawal period</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Major Species</strong></td>
<td><strong>Minor Species</strong></td>
</tr>
<tr>
<td><strong>LOD (n &gt; 20 blank samples)</strong></td>
<td><strong>Major Species</strong></td>
</tr>
<tr>
<td>LOQ (as per VICH GL49)</td>
<td></td>
</tr>
<tr>
<td>Accuracy:</td>
<td></td>
</tr>
<tr>
<td>3 analyte levels (1/2MRL-2xMRL), n=6/level</td>
<td>Determination of LOQ, accuracy and precision can be combined</td>
</tr>
<tr>
<td>Precision:</td>
<td>The method should be validated in respect of the LOQ and for accuracy and precision at the level of the MRL and half the MRL.</td>
</tr>
<tr>
<td>Repeatability:</td>
<td>With regard to specificity, possible interference from matrix components and from chemically closely related substances used in veterinary medicine should be investigated.</td>
</tr>
<tr>
<td>3 analyte levels (1/2MRL, MRL, 2xMRL), n=6/level</td>
<td>Adequate storage and sample processing stability data should also be supplied.</td>
</tr>
<tr>
<td>Within Laboratory Reproducibility</td>
<td></td>
</tr>
<tr>
<td>3 analyte levels (1/2MRL, MRL, 2xMRL), n=6 at n ≥3 separate days</td>
<td></td>
</tr>
<tr>
<td>Specificity against homologues/analogues</td>
<td></td>
</tr>
</tbody>
</table>

See VICH GL49.
The following legislation, guidelines and notes for guidance are relevant to this guideline:


4. Directive 2010/63/EC (regarding the protection of animals used for experimental and other scientific purposes).

5. Commission Regulation (EU) 2017/880 of 23 May 2017 laying down rules on the use of a maximum residue limit established for a pharmacologically active substance in a particular foodstuff for another foodstuff derived from the same species and a maximum residue limit established for a pharmacologically active substance in one or more species for other species, in accordance with Regulation (EC) No 470/2009 of the European Parliament and of the Council


   - CVMP Guideline on user safety for pharmaceutical veterinary medicinal products (EMEA/CVMP/543/03-Rev.1)
   - CVMP Guideline on user safety of topical administered products (EMEA/CVMP/SWP/721059/2014)
   - CVMP Note for guidance for the assessment of the effect of antimicrobial substances on dairy starter cultures (EMEA/CVMP/276/99-FINAL)
   - CVMP Note for guidance on the establishment of maximum residue limits for minor animal species (EMEA/CVMP/153a/97-FINAL)
   - CVMP Note for guidance on the establishment of maximum residue limits for Salmonidae and other fin fish (EMEA/CVMP/153b/97-FINAL)
- CVMP Note for guidance on the risk analysis approach for residues of veterinary medicinal products in food of animal origin (EMEA/CVMP/187/00-FINAL).

- VICH GL6: Environmental Impact Assessment (EIAs) for Veterinary Medicinal Products – Phase I (CVMP/VICH/592/98-FINAL)

- VICH GL22: Studies to evaluate the safety of residues of veterinary drugs in food: reproduction testing (CVMP/VICH/525/2000)

- VICH GL23: Studies to evaluate the safety of residues of veterinary drugs in food: genotoxicity testing (CVMP/VICH/526/2000)

- VICH GL28: Studies to evaluate the safety of residues of veterinary drugs in food: carcinogeticity testing (CVMP/VICH/645/2001 Rev.1)

- VICH GL31: Studies to evaluate the safety of residues of veterinary drugs in food: repeat-dose (90 days) toxicity testing (CVMP/VICH/484/2002)

- VICH GL32: Studies to evaluate the safety of residues of veterinary drugs in food: developmental toxicity testing (CVMP/VICH/485/2002)

- VICH GL33: Studies to evaluate the safety of residues of veterinary drugs in human food: general approach to testing (EMEA/CVMP/VICH/486/02-Rev.2)

- VICH GL36: Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: metabolism study to determine the quantity and identify the nature of residues (EMA/CVMP/VICH/463072/2009)

- VICH GL46: Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: laboratory animal comparative metabolism studies (EMA/CVMP/VICH/463104/2009)

- VICH GL47: Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: marker residue depletion studies to establish product withdrawal periods (EMA/CVMP/VICH/463202/2009)

- VICH GL56: Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing animals: study design recommendations for residue studies in honey for establishing MRLs and withdrawal periods (EMA/CVMP/VICH/176637/2014)

- VICH GL57: Studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing species: marker residue depletion studies to establish product withdrawal periods in aquatic species (Draft: EMA/CVMP/VICH/517152/2013)